Technos look superbly poised for upward quantum re-rate nigh.
Rights issue technically holding it back a little (theoretically) ... but ends next Thursday.
Judging by similar rights issues in NTU and AEE, share price has already been adjusted for it and cos of minimal size, should not pose any further down-pressure.
Fundamentals support above thoughts in that :
(1) Mt Clements drilling has just begun and is a high grade Gold + Silver + Copper play with portion open-pittable and with NST 20% partner which has the CASHFLOW and is likley to make a move on ARV at some stage ... with all three metals in serious upward travel mode atm;
(2) Yandals gold potential looks larger and more interesting longer term so plenty of spec potential further out;
(3) HREEs is the sleeper and also main reason I have decided to add this to my emerging Olympians portfolio, tho no emphasis yet given by company re this ... hence explosive upside if they can confirm auger samples show LENGTHY strike is mineralised with HREEs ...
Market mood is HOT for REEs and ARV doesnt appear yet recognised as the serious emerging HREEs player it obviously is, based the history emerging on HC !
(4) Market cap is "right" for the multiples upside reward / risk and now has the cash (coming) to do it justice ... short-term triggers can come from Mt Clements drilling and / or market recognition of WA HREEs potential.
And being the leverage player I am when I sniff a new play "ripe for the picking" with all boxes ticked, happy to keep accumulating OBs now at an av 1.2c time premium increment for the 9 months remaining life and given the low 5c convwersion ... we shld know what ARV are all about well before then !
STRONG spec buy for mine at current levels ... watch this space.
IMBOOC
- Forums
- ASX - By Stock
- ARV
- chartwatch
chartwatch, page-10
-
- There are more pages in this discussion • 22 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add ARV (ASX) to my watchlist
|
|||||
Last
1.0¢ |
Change
-0.001(9.09%) |
Mkt cap ! $19.16M |
Open | High | Low | Value | Volume |
1.1¢ | 1.1¢ | 1.0¢ | $36.62K | 3.486M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
20 | 6127936 | 1.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
1.1¢ | 2451489 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 8845 | 0.013 |
1 | 20000 | 0.011 |
16 | 4947930 | 0.010 |
8 | 2698995 | 0.009 |
4 | 2020000 | 0.008 |
Price($) | Vol. | No. |
---|---|---|
0.011 | 3068516 | 3 |
0.012 | 8074827 | 7 |
0.013 | 1592062 | 6 |
0.014 | 1326916 | 2 |
0.015 | 666278 | 6 |
Last trade - 16.10pm 15/07/2024 (20 minute delay) ? |
Featured News
ARV (ASX) Chart |
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online